FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Company ProfileYarrow Bioscience Inc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
YARW
Yarrow Bioscience Inc Stock AnalysisComprehensive stock analysis for Yarrow Bioscience Inc (YARW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisYARW
YARW
Yarrow Bioscience Inc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
YARW
Home🔹Stocks🔹Yarrow Bioscience Inc

Yarrow Bioscience Inc

🇺🇸YARW•NASDAQ

Yarrow Bioscience Inc

🇺🇸YARW•NASDAQ
Market cap
$439.19K
Sentiment

Your view on YARW

Mkt Cap
$439.19K
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Yarrow Bioscience Inc

Industry
Biotechnology
Sector
Healthcare
CEO
David Domzalski
Headquarters
470 James Street, Suite 007, New Haven, CT, US
Industry
Biotechnology
Sector
Healthcare
CEO
David Domzalski
Headquarters
470 James Street, Suite 007, New Haven, CT, US
Description

Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases.

The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Yarrow Bioscience Inc, and the rating behind it. YARW last traded at $25.54; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Yarrow Bioscience Inc. Starting points for Yarrow Bioscience Inc: EPS -$21.81, beta 2.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Yarrow Bioscience Inc. Yarrow Bioscience Inc paid $20.10 per share over the last year — a 78.7% yield at the current $25.54 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Yarrow Bioscience Inc. Trailing twelve-month EPS for Yarrow Bioscience Inc stands at -$21.81. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Yarrow Bioscience Inc. Yarrow Bioscience Inc has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Yarrow Bioscience Inc valued side by side against its closest peers. Yarrow Bioscience Inc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Yarrow Bioscience Inc, and how their positions are changing. At a $439,186 market value, institutional positions materially move Yarrow Bioscience Inc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Yarrow Bioscience Inc executives and directors. Shares of Yarrow Bioscience Inc have traded between $14.05 and $46.95 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Yarrow Bioscience Inc. Yarrow Bioscience Inc is a $439,186 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Yarrow Bioscience Inc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Yarrow Bioscience Inc. Coverage tracks Yarrow Bioscience Inc within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

Peer companies

  • AIMAIM ImmunoTech Inc.
  • BCLIBrainstorm Cell Therapeutics Inc.
  • ENSCEnsysce Biosciences, Inc.
  • KALAKALA BIO, Inc.
  • KTTAPasithea Therapeutics Corp.
  • MTNBMatinas BioPharma Holdings, Inc.
  • QNRXQuoin Pharmaceuticals, Ltd.
  • SNGXSoligenix, Inc.

More Biotechnology companies

  • MLECWMoolec Science S.A.
  • MLLCFMolecular Partners AG
  • MLTXMoonLake Immunotherapeutics
  • MLYSMineralys Therapeutics, Inc.
  • MMIRFMedMira Inc.
  • MNKDMannKind Corporation
  • MNOVMediciNova, Inc.
  • MNPRMonopar Therapeutics Inc.
  • MOLNMolecular Partners AG
  • MPLTMapLight Therapeutics, Inc.
  • MREOMereo BioPharma Group plc
  • MRESInstitute of Biomedical Research Corp.

ETFs holding Yarrow Bioscience Inc

Largest holders, then the funds most concentrated in YARW · % = share of the fund

  • VXFVanguard Extended Market ETF0.00%
  • DFASDimensional - US Small Cap ETF0.00%
  • DFMCU.S. Micro Cap Portfolio ETF0.00%

News

Latest Market News